Changing the Therapeutic and the Treatment Landscape

Improved Treatment through Improved Technology

RenBio’s MYO Technology is compatible with any gene-encoded protein product and serves as a true platform technology with the potential to fundamentally change the landscape of protein-based therapeutics. Protein therapeutics, including antibodies, are currently used for numerous diseases with many more in clinical development.

The increased usage of antibodies and other therapeutic proteins has greatly improved the standard of care for patients. RenBio’s MYO Technology builds upon these advancements and revolutionizes the treatment landscape.

Antibodies and other therapeutic proteins have revolutionized disease treatment

Therapeutic proteins are an increasingly important class of biologics that are being extensively utilized in the treatment of diseases such as cancer, arthritis, blood disorders, and viral infections. These therapeutics, such as antibodies, growth factors, and cytokines, can be manufactured and delivered to patients in order to exert their potent effects for the treatment and prevention of disease.

Therapeutic proteins can initiate critical processes for fighting infections, inhibiting abnormal tissue growth or immune function, or stimulating the production of cellular products.

But the method of delivery to patients is in need of innovation

In order to manufacture antibodies and other therapeutic proteins, they must be produced in living cells cultured in a laboratory, which requires large, specialized facilities. And because the level of these proteins in the body declines over time after they are administered, they must be frequently dosed to maintain levels adequate for clinical effectiveness. This translates into high costs for most of these types of medicines.

RenBio is revolutionizing antibody and therapeutic protein delivery

Our MYO (Make Your Own) Technology is built to revolutionize the state of antibody and protein therapeutics by empowering patients to produce their own medicines.

In doing so, we are creating radically new therapies that are longer-lasting than those delivered using standard methods. Our bodies already know how to produce proteins, so why not provide patients with the DNA blueprint for protein therapeutics instead of a manufactured product?

MYO administration is easy

Protein-encoding DNA molecules are injected into a patient’s muscle, then short electrical pulses are applied, allowing the DNA to enter the muscle cells.

MYO administration is easy

Protein-encoding DNA molecules are injected into a patient’s muscle, then short electrical pulses are applied, allowing the DNA to enter the muscle cells.

MYO Technology is simple

Once inside the cell, the cell’s own protein production machinery takes over; muscle cells begin synthesizing the protein molecules. These proteins are then rapidly released into the bloodstream and from there, travel to other parts of the body to perform their disease-fighting functions

MYO Technology requires fewer treatments

Because the protein-encoding DNA is stable in muscle cells for several months, the therapeutic proteins are continually produced throughout this period, resulting in fewer treatments than with traditional delivery methods.

Learn more about MYO Applications